Results 51 to 60 of about 8,627 (176)
International Journal of Dental Hygiene, EarlyView.ABSTRACT Objectives The aim of this work is to assess and compare the impact of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKA) during and immediately after periodontal nonsurgical therapy. Materials and Methods A prospective observational cohort study was conducted with patients who presented a history of cardiovascular disease ...
F. Berton +5 more
wiley +1 more source
An Unusual Side Effect of Dabigatran Etexilate Use - Acute Renal Failure
Eurasian Journal of Emergency Medicine, 2019 Dabigatran etexilate is a prodrug with anticoagulant effect through inhibition of thrombin. Although it does not require laboratory monitoring and has minimal food-drug interaction, its disadvantages are bleeding, common GIS-related side effects and the ...
Ekim Sağlam Gürmen, Adnan Bilge
doaj +1 more source
Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.ABSTRACT The 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase inhibitor rosuvastatin is a substrate of breast cancer resistance protein (BCRP). BCRP inhibition increases rosuvastatin plasma concentrations and may result in concentration‐dependent muscle toxicity, at worst rhabdomyolysis.
Ronja Levomäki +3 more
wiley +1 more source
Hepatology Research, Volume 56, Issue 8, Page 1202-1212, August 2026.ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi +6 more
wiley +1 more source
Prescribing trends for dabigatran etexilate in primary care. [PDF]
, 2012 At the time of the analysis, dabigatran etexilate was licensed, in Ireland, for thromboprophylaxis in adults after elective total hip- and total knee-replacement only.
McCullagh, L, Barry, M
core
Stability of Dabigatran Etexilate in Manufacturer’s Blister Pack, Unit-Dose Packaging, and Community Pharmacy Blister Pack [PDF]
, 2015 Background: Dabigatran, a direct thrombin inhibitor, is indicated for the prevention and treatment of venous thromboembolism and for stroke prophylaxis in atrial fibrillation.
Semchuk, William +4 more
core +1 more source
Thrombosis Journal, 2012 Background There has been a shift towards greater use of neuraxial over general anaesthesia for patients undergoing total hip or knee arthroplasty. Furthermore, suggestions that peripheral nerve block may reduce adverse effects have recently been put ...
Rosencher Nadia +5 more
doaj +1 more source
Case Reports in Medicine, 2013 Introduction. Dabigatran is an oral direct thrombin inhibitor which has been approved for prophylaxis of stroke in patients with atrial fibrillation. The use of dabigatran etexilate increased rapidly due to many benefits.
Joonseok Kim +6 more
doaj +1 more source
Brain and Behavior, Volume 16, Issue 6, June 2026.ABSTRACT Objective This study aimed to identify and characterize drugs associated with reports of head injury through a comprehensive analysis of the FDA Adverse Event Reporting System (FAERS) database. Methods A retrospective disproportionality analysis was conducted on FAERS reports from 2004 to 2023.
Jiaqi Guo +5 more
wiley +1 more source
Epileptic Disorders, Volume 28, Issue 3, Page 855-867, June 2026.Abstract Objectives Antiseizure medications (ASMs) can induce the activity of drug‐metabolizing enzymes and drug transporters, including cytochrome P450 (CYP)2C9 and P‐glycoprotein (P‐gp). Our objective was to comparatively assess the effects of ASMs on exposure to clinical CYP2C9 and P‐gp substrates.
Hagar Cohen +4 more
wiley +1 more source